Background
The incidence of neuroendocrine tumors (NETs) has been increasing in recent decades and there has been a rising awareness by the physicians for the diagnosis of NETs. Several novel agents have been developed and demonstrated to improve the survival of NETs recently. Previously, we reported the incidence and survival of NETs in Taiwan by analyzing the 1996–2008 data from the Taiwan Cancer Registry (TCR). Here we performed an updated analysis on the incidence and survival of NETs in Taiwan from 1996 to 2015.
Methods
Data for the current analysis were obtained from the TCR and the Death Registry Database. The incidence was age-standardized to the WHO 2000 population and the overall survival was calculated by life-table method. The risk of NETs death was evaluated by performing Cox proportional hazards regression analysis.
Results
There were a total of 7,760 cases of NETs diagnosed during 1996–2015. The most common site of NETs was rectum (29.65%), followed by lung and bronchus (17.22%), and pancreas (10.71%). The incidence of NETs was 0.244 per 100,000 in 1996 and increased to 3.162 per 100,000 in 2015 with an annual percentage change (APC) of 15.44 (P < 0.0001). The site with the most rapid increase was pancreas with an APC of 28.04 (P < 0.0001). The 5- and 10-year survival rates of all NETs were 54.6% and 45.3%, respectively. Female and younger NETs patients had a better survival. The HR for survival of all NETs diagnosed between 2010 and 2015 was 0.91 (95%CI, 0.84–0.99) compared to those diagnosed between 2004 and 2009. Among the common sites of NETs, an improved survival of NETs diagnosed between 2010 and 2015 compared to those diagnosed between 2004 and 2009 was only observed in pancreatic NET (HR = 0.52, 95% CI, 0.41–0.66). This result was likely due to the early diagnosis and improvement in the treatment of pancreatic NET.
Conclusions
Overall, the incidence of NETs in Taiwan has continued to increase. The survival of pancreatic NET has shown recent improvement. The development of novel therapeutic agents has the potential to improve the prognosis of NETs of other primary sites in the near future.